{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:23:51Z","timestamp":1787505831523,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jcf.2025.08.004","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:09:35Z","timestamp":1757131775000},"page":"1067-1072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Routine cell-free DNA prenatal screening identifies pregnancies at high risk for cystic fibrosis that may benefit from fetal therapy"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5220-6022","authenticated-orcid":false,"given":"J.","family":"Wynn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Chandler-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8590-5911","authenticated-orcid":false,"given":"A.","family":"Talati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-8846","authenticated-orcid":false,"given":"M.","family":"Zaretsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4290-8044","authenticated-orcid":false,"given":"A.","family":"Trimble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.08.004_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/s41436-018-0321-0","article-title":"Clinical utility of expanded carrier screening: results-guided actionability and outcomes","author":"Johansen Taber","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.jcf.2025.08.004_bib0002","unstructured":"American College of Obstetricians and Gynecologists\u2019 Committee on Genetics (2017) Number 691: ccarrier screening for genetic conditions | ACOG."},{"key":"10.1016\/j.jcf.2025.08.004_bib0003","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ppul.26209","article-title":"Detection of disease-causing CFTR variants in state newborn screening programs","volume":"58","author":"McGarry","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.08.004_bib0004","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jcf.2010.02.005","article-title":"Benchmarks for Cystic Fibrosis carrier screening: a European consensus document","volume":"9","author":"Castellani","year":"2010","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.08.004_bib0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/pd.5611","article-title":"International perspectives on the implementation of reproductive carrier screening","volume":"40","author":"Delatycki","year":"2020","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.jcf.2025.08.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1071\/PY21247","article-title":"Reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome and spinal muscular atrophy: patterns of community and healthcare provider participation in a Victorian screening program","volume":"28","author":"Leibowitz","year":"2022","journal-title":"Aust J Prim Health"},{"key":"10.1016\/j.jcf.2025.08.004_bib0007","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/pd.5900","article-title":"Evaluating the efficacy of three carrier screening workflows designed to identify at-risk carrier couples","volume":"41","author":"Arjunan","year":"2021","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.jcf.2025.08.004_bib0008","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/pd.5588","article-title":"It takes two: uptake of carrier screening among male reproductive partners","volume":"40","author":"Giles Choates","year":"2020","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.jcf.2025.08.004_bib0009","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pd.5824","article-title":"Reproductive male partner testing when the female is identified to be a genetic disease carrier","volume":"41","author":"Simone","year":"2021","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.jcf.2025.08.004_bib0010","article-title":"The completion of indicated paternal prenatal genetic and carrier testing at a public hospital in Los Angeles, California","volume":"1","author":"Nguyen","year":"2023","journal-title":"Genet Med Open"},{"key":"10.1016\/j.jcf.2025.08.004_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100858","article-title":"Barriers to completion of expanded carrier screening in an inner City population","author":"Strauss","year":"2023","journal-title":"Genet Med"},{"key":"10.1016\/j.jcf.2025.08.004_bib0012","first-page":"157","article-title":"How should preconceptional cystic fibrosis carrier screening be provided? Opinions of potential providers and the target population","volume":"6","author":"Poppelaars","year":"2003","journal-title":"Community Genet"},{"key":"10.1016\/j.jcf.2025.08.004_bib0013","first-page":"858","article-title":"Should clinicians leave \u201cexpanded\u201d carrier screening decisions to patients?","volume":"21","author":"Fakih","year":"2019","journal-title":"Am Med Assoc J Ethics"},{"key":"10.1016\/j.jcf.2025.08.004_bib0014","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/pd.4585","article-title":"Non-invasive prenatal diagnosis for cystic fibrosis: detection of paternal mutations, exploration of patient preferences and cost analysis","volume":"35","author":"Hill","year":"2015","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.jcf.2025.08.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/pd.6427","article-title":"Performance of single-gene noninvasive prenatal testing for autosomal recessive conditions in a general population setting","volume":"43","author":"Wynn","year":"2023","journal-title":"Prenat Diagn"},{"key":"10.1016\/j.jcf.2025.08.004_bib0016","first-page":"1","article-title":"Maternal carrier screening with single-gene NIPS provides accurate fetal risk assessments for recessive conditions","volume":"25","author":"Hoskovec","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.jcf.2025.08.004_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50378-8","article-title":"A novel high-throughput molecular counting method with single base-pair resolution enables accurate single-gene NIPT","volume":"9","author":"Tsao","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2025.08.004_bib0018","article-title":"A review of Trikafta: triple Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"CureusCureus"},{"key":"10.1016\/j.jcf.2025.08.004_bib0019","article-title":"Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis","author":"Metcalf","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.08.004_bib0020","first-page":"47","article-title":"Pregnancy in people with cystic fibrosis treated with highly effective modulator therapy","volume":"145","author":"Goralski","year":"2025","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jcf.2025.08.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.03.009","article-title":"Sermet-Gaudelus I; MODUL-CF study group. First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: rreport from the MODUL-CF study","author":"Bonnel","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.08.004_bib0022","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2025.03.006","article-title":"CFTR modulator therapy via carrier mother to treat meconium ileus in a F508del homozygous fetus: iinsights from an unsuccessful case","volume":"24","author":"Destoop","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.08.004_bib0023","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2025.08.004_bib0024","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41436-021-01203-z","article-title":"ACMG Professional Practice and Guidelines Committee. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Gregg","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.jcf.2025.08.004_bib0025","unstructured":"The clinical and functional TRanslation of CFTR (CFTR2). http:\/\/cftr2.org. Accessed 10 Nov 2024."},{"key":"10.1016\/j.jcf.2025.08.004_bib0026","unstructured":"CFTR-France Database. https:\/\/cftr.chu-montpellier.fr\/. Accessed 10 Nov 2024."},{"key":"10.1016\/j.jcf.2025.08.004_bib0027","unstructured":"FDA approves Trikafta for 94 additional rare CFTR mutations | Cystic Fibrosis Foundation. https:\/\/www.cff.org\/news\/2024-12\/fda-approves-trikafta-additional-rare-cftr-mutations. Accessed 27 Jan 2025."},{"key":"10.1016\/j.jcf.2025.08.004_bib0028","unstructured":"Recommended uniform screening panel | HRSA. https:\/\/www.hrsa.gov\/advisory-committees\/heritable-disorders\/rusp. Accessed 5 Feb 2025."},{"key":"10.1016\/j.jcf.2025.08.004_bib0029","unstructured":"R Core Development Team (2018) R: a language and environment for statistical computing."},{"key":"10.1016\/j.jcf.2025.08.004_bib0030","unstructured":"(2016) United States Census Bureau. https:\/\/www.census.gov. Accessed 27 Jan 2025."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:36:25Z","timestamp":1779953785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325015632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1569199325015632"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.08.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Routine cell-free DNA prenatal screening identifies pregnancies at high risk for cystic fibrosis that may benefit from fetal therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 BillionToOne Inc. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}